Trial Profile
A phase III randomized study of CHOP chemotherapy [cyclophosphamide, doxorubicin, vincristine, and prednisone] plus Rituxan (IDEC-C2B8) [rituximab] versus CHOP chemotherapy alone for newly diagnosed, previously untreated, aggressive non-Hodgkin's lymphoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Dec 2023
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 11 Sep 2005 New trial record.